Skip to content

R&D at other companies

Merck & Co. logo
Merck & Co.MRK
$12.59B+248%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$95.73M+35.0%
CG Oncology logo
CG OncologyCGON
$43.73M+59.2%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$8.09M-32.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$25.22M-31.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s R&D?
Aura Biosciences, Inc. (AURA) reported R&D of $27.96M in Q1 2026.
How has Aura Biosciences, Inc.'s R&D changed year-over-year?
Aura Biosciences, Inc.'s R&D increased by 19.8% year-over-year, from $23.34M to $27.96M.
What is the long-term trend for Aura Biosciences, Inc.'s R&D?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s R&D has grown at a 37.6% compound annual growth rate (CAGR), from $25.16M to $90.3M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.